Filing Flows

Filing Flows › 8-K events › Pelthos Therapeutics

Pelthos Therapeutics: entry into a material definitive agreement

Form 8-K filed Oct 30, 2026 · items 1.01, 2.03, 3.02, 3.03, 5.02, 5.03, 5.07, 7.01

Mergers and acquisitionsPelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin

What the filing says

On October 30, 2026, Pelthos Therapeutics Inc., a Nevada corporation (“ Pelthos ” or “ Public Company ”), Credit Card Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pelthos (“ Merger Sub ”), Credit Card Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Pelt

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Item 3.02: +0.1% next session across 2,750. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Pelthos Therapeutics at a glance

Latest quarterQ2 2026
Revenue$15.6M
Operating margin-111.0%
IndustryBiological Products, (No Diagnostic Substances)

Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%. The chart follows the revenue to costs, profit and cash.

Pelthos Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.